Jules P.P. Meijerink

12.5k total citations · 2 hit papers
132 papers, 7.4k citations indexed

About

Jules P.P. Meijerink is a scholar working on Public Health, Environmental and Occupational Health, Molecular Biology and Hematology. According to data from OpenAlex, Jules P.P. Meijerink has authored 132 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Public Health, Environmental and Occupational Health, 60 papers in Molecular Biology and 55 papers in Hematology. Recurrent topics in Jules P.P. Meijerink's work include Acute Lymphoblastic Leukemia research (69 papers), Chronic Myeloid Leukemia Treatments (36 papers) and Acute Myeloid Leukemia Research (34 papers). Jules P.P. Meijerink is often cited by papers focused on Acute Lymphoblastic Leukemia research (69 papers), Chronic Myeloid Leukemia Treatments (36 papers) and Acute Myeloid Leukemia Research (34 papers). Jules P.P. Meijerink collaborates with scholars based in Netherlands, United States and Belgium. Jules P.P. Meijerink's co-authors include Rob Pieters, Anna Velcich, Alexandra W. C. Einerhand, Hans A. Büller, Ingrid B. Renes, Maria van der Sluis, Barbara A. E. de Koning, Johannes B. van Goudoever, Isabelle Van Seuningen and Adrianus C. J. M. de Bruijn and has published in prestigious journals such as Nature Medicine, Nature Communications and Nature Genetics.

In The Last Decade

Jules P.P. Meijerink

131 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Muc2-Deficient Mice Spontaneously Develop Colitis, Indicating That MUC2 Is Critical for Colonic Protection

2006 1.3k citations Jules P.P. Meijerink et al. profile →
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors

2007 523 citations Jules P.P. Meijerink, Rob Pieters et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jules P.P. Meijerink Netherlands	48	3.9k	2.2k	1.9k	1.5k	1.3k	132	7.4k
Michelle A. Kelliher United States	52	6.8k 1.8×	1.2k 0.5×	1.4k 0.7×	1.6k 1.1×	5.1k 3.8×	95	10.9k
Ursula R. Kees Australia	37	2.4k 0.6×	876 0.4×	989 0.5×	751 0.5×	1.3k 1.0×	138	4.8k
Benjamin T. Kile Australia	50	4.6k 1.2×	388 0.2×	1.9k 1.0×	1.5k 0.9×	2.8k 2.1×	137	8.3k
Grover C. Bagby United States	46	2.7k 0.7×	379 0.2×	1.7k 0.9×	870 0.6×	1.3k 1.0×	130	5.6k
Kazuhiro Morishita Japan	33	2.7k 0.7×	301 0.1×	1.3k 0.7×	799 0.5×	1.2k 0.9×	143	4.9k
David Kägi Switzerland	28	3.0k 0.8×	420 0.2×	719 0.4×	1.3k 0.8×	4.8k 3.6×	37	8.2k
DW Golde United States	45	1.6k 0.4×	359 0.2×	2.0k 1.0×	1.1k 0.7×	2.4k 1.8×	126	6.2k
Yasusada Miura Japan	41	2.3k 0.6×	297 0.1×	2.1k 1.1×	1.6k 1.0×	2.6k 1.9×	280	7.3k
Eric M. Pietras United States	30	2.5k 0.7×	321 0.1×	2.4k 1.2×	698 0.5×	3.3k 2.5×	69	6.6k
Michael Hahne France	41	5.9k 1.5×	325 0.1×	483 0.2×	2.1k 1.4×	5.5k 4.2×	96	10.6k

Countries citing papers authored by Jules P.P. Meijerink

Since Specialization

Citations

This map shows the geographic impact of Jules P.P. Meijerink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jules P.P. Meijerink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jules P.P. Meijerink more than expected).

Fields of papers citing papers by Jules P.P. Meijerink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jules P.P. Meijerink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jules P.P. Meijerink. The network helps show where Jules P.P. Meijerink may publish in the future.

Co-authorship network of co-authors of Jules P.P. Meijerink

This figure shows the co-authorship network connecting the top 25 collaborators of Jules P.P. Meijerink. A scholar is included among the top collaborators of Jules P.P. Meijerink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jules P.P. Meijerink. Jules P.P. Meijerink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bladergroen, Reno S., Lennart Kester, Marijn A. Vermeulen, et al.. (2024). T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions. PubMed. 1(3). 100029–100029. 2 indexed citations

Smits, Willem K., Carlo Vermeulen, Shunsuke Kimura, et al.. (2023). Elevated enhancer-oncogene contacts and higher oncogene expression levels by recurrent CTCF inactivating mutations in acute T cell leukemia. Cell Reports. 42(4). 112373–112373. 5 indexed citations

Chonghaile, Tríona Ní, Melissa Burns, Kristen E. Stevenson, et al.. (2022). JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia. 36(6). 1499–1507. 18 indexed citations

Padilla, Laura, Judith M. Boer, Melanie M. Hagleitner, et al.. (2022). Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement. Cancers. 14(16). 3895–3895. 6 indexed citations

Canté-Barrett, Kirsten, Mariska T. Meijer, Valentina Cordo’, et al.. (2022). MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus. JCI Insight. 7(13). 16 indexed citations

Buijs-Gladdines, Jessica G. C. A. M., Valentina Cordo’, Willem K. Smits, et al.. (2021). MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia. 35(12). 3394–3405. 35 indexed citations

Almeida, Afonso R. M., Sofie Demeyer, Thea Hogan, et al.. (2021). Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 138(12). 1040–1052. 28 indexed citations

Butler, Miriam, Dorette S. van Ingen Schenau, Jiangyan Yu, et al.. (2021). BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway. Blood. 138(23). 2383–2395. 17 indexed citations

Meijerink, Jules P.P.. (2021). BCL11B, the Cerberus of human leukemia. Blood. 138(9). 741–743. 2 indexed citations

10.

Loeffen, Jan, et al.. (2020). T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?. Blood Advances. 4(14). 3466–3473. 34 indexed citations

11.

Bock, Charles E. de, Sofie Demeyer, Sandrine Degryse, et al.. (2018). HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discovery. 8(5). 616–631. 70 indexed citations

12.

Canté-Barrett, Kirsten, Yunlei Li, Eric Vroegindeweij, et al.. (2017). Loss of CD44dim Expression from Early Progenitor Cells Marks T-Cell Lineage Commitment in the Human Thymus. Frontiers in Immunology. 8. 32–32. 36 indexed citations

13.

Canté-Barrett, Kirsten, J A P Spijkers-Hagelstein, Jessica G. C. A. M. Buijs-Gladdines, et al.. (2016). MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia. 30(9). 1832–1843. 79 indexed citations

14.

Stein, Sarah, Kostandin V. Pajcini, Takuya Ohtani, et al.. (2016). Trib2 Suppresses Tumor Initiation in Notch-Driven T-ALL. PLoS ONE. 11(5). e0155408–e0155408. 16 indexed citations

15.

Iterson, Maarten van, Floor A.M. Duijkers, Jules P.P. Meijerink, et al.. (2012). A Novel and Fast Normalization Method for High-Density Arrays. Statistical Applications in Genetics and Molecular Biology. 11(4). 2 indexed citations

16.

Szczepański, Tomasz, Vincent H. J. van der Velden, Esmé Waanders, et al.. (2011). Late Recurrence of Childhood T-Cell Acute Lymphoblastic Leukemia Frequently Represents a Second Leukemia Rather Than a Relapse: First Evidence for Genetic Predisposition. Journal of Clinical Oncology. 29(12). 1643–1649. 51 indexed citations

17.

Grotel, Martine van, Jules P.P. Meijerink, Elisabeth R. van Wering, et al.. (2007). Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia. 22(1). 124–131. 91 indexed citations

18.

Bergh, Anne R. M. von, Ellen van Drunen, Elisabeth R. van Wering, et al.. (2006). High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes Chromosomes and Cancer. 45(8). 731–739. 59 indexed citations

19.

Wiemer, Erik A.C., A. Prins, Jules P.P. Meijerink, et al.. (2002). Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia. 16(5). 833–839. 139 indexed citations

20.

Hackstein, Johannes H. P., Ute Mackenstedt, Heinz Mehlhorn, et al.. (1995). Parasitic apicomplexans harbor a chlorophyll a-D1 complex, the potential target for therapeutic triazines. Parasitology Research. 81(3). 207–216. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact